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Abstract: The glucagon receptor (GCGR) is emerging as an important target in anti-diabetic therapy, especially as
part of the pharmacology of dual glucagon-like peptide-1/glucagon (GLP-1/GCG) receptor agonists. However,
currently, there are no suitable biomarkers that reliably demonstrate GCG receptor target engagement.
Methods: Two potent GCG receptor peptide agonists, S01-GCG and S02-GCG, were labeled with positron emission
tomography (PET) radionuclide gallium-68. The GCG receptor binding affinity and specificity of the resulting
radiopharmaceuticals [68Ga]Ga-DO3A-S01-GCG and [68Ga]Ga-DO3A-S02-GCG were evaluated in HEK-293 cells
overexpressing the human GCG receptor and on frozen hepatic sections from human, non-human primate, and rat.
In in vivo biodistribution, binding specificity and dosimetry were assessed in rat.
Results: [68Ga]Ga-DO3A-S01-GCG in particular demonstrated GCG receptor-mediated binding in cells and liver
tissue with affinity in the nanomolar range required for imaging. [68Ga]Ga-DO3A-S01-GCG binding was not blocked
by co-incubation of a GLP-1 agonist. In vivo binding in rat liver was GCG receptor specific with low non-specific
binding throughout the body. Moreover, the extrapolated human effective doses, predicted from rat biodistribution
data, allow for repeated PET imaging potentially also in combination with GLP-1R radiopharmaceuticals.
Conclusion: [68Ga]Ga-DO3A-S01-GCG thus constitutes a first-in-class PET tracer targeting the GCG receptor, with
suitable properties for clinical development. This tool has potential to provide direct quantitative evidence of GCG
receptor occupancy in humans.
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Introduction
Type 2 diabetes (T2D) affects hundreds of millions of indi-
viduals worldwide and causes great strain on healthcare
systems globally [1]. Advancement of novel anti-diabetic
treatments are therefore of utmost importance. The gluca-
gon receptor (GCGR) is emerging as an important target in
anti-diabetic therapy, especially as part of the pharmacology
of dual glucagon-like peptide-1/glucagon (GLP-1/GCG) re-
ceptor agonists [2–4]. GLP1R activation has been shown to
decrease blood glucose (due to the incretin effect via bind-
ing to the receptor in the pancreas), to reduce appetite and
induce weight loss while agonism on the GCGR in the liver
on the other hand has been shown to increase energy
expenditure in addition to inducing weight loss. Thus, pep-
tides binding both the GLP1R and GCGR are expected to
combine these effects in the same molecule.
We have previously developed a target engagement
marker for the glucagon-like peptide-1 receptor (GLP-1R),
the positron emission tomography (PET) ligand
[68Ga]Ga-DO3A-VS-Cys40-Exendin-4, which enables
quantitative measurements of GLP-1R occupancy in living
subjects [5–9]. Additionally, drug interaction with the
GLP-1R can be assessed indirectly and qualitatively by
pharmacology such as nausea. However, there is a lack of
biomarkers for in vivo drug pharmacology on the GCGR,
especially in the context of GLP-1R/GCGR dual agonists.
Demonstrating target engagement on the GCCR remains
challenging since the dual agonists activate hormone re-
ceptors with overlapping pharmacology, as well as poten-
tial cross-binding to the GLP1R.
For GLP-1/GCG receptor dual agonists, knowledge
about the proportion of occupied receptors in vivo could
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promote the understanding of the pharmacological ef-
fects in terms of weight loss and glycemic control. The
development of in vivo target engagement markers
would therefore support development of dual agonists,
by allowing direct measurements of drug interactions at
the GCGR.
We report herein on the development and preclinical
evaluation of two first-in-class PET imaging agent candi-
dates with potential for in vivo determination of GCGR
occupancy in humans.
Materials and methods
Peptides
The peptides S01-GCG and S02-GCG were developed by
Sanofi based on exendin-4 as peptide backbone with se-
lective amino acid mutations to achieve selectivity for the
GCG receptor. Based on prior work on selective glucagon
receptor agonist as rescue medicine for the treatment of
severe hypoglycemia, we developed S02-GCG attaching
the chelating unit DO3A via a cysteine on the c-terminus
and a diethylsulfone linker. For S01-GCG, we introduced
a lactam bridge between Glu16 and Lys20 to stabilize the
alpha-helical fold of the peptide backbone, thereby not
only increasing binding affinity and selectivity towards the
GCGR but also improving metabolic stability to enhance
clearance of the intact PET tracer by the kidneys. To fur-
ther optimize metabolic stability, we changed the serine in
position 2 to a D-serine to block against DPP-IV cleavage
and mutated the arginine in position 17 to a glutamate,
thereby removing the RR cleavage motif observed in glu-
cagon. See Additional file 1 for details on peptide
synthesis.
In vitro potency assay
The potency of DO3A-S01-GCG and DO3A-S02-GCG
was assessed by a functional cAMP assay in HEK293 cells
transfected with human, cynomolgus non-human primate
(NHP), or rat GCGR (EvoTec, Hamburg, Germany). The
same assay was performed for GLP-1R to assess
cross-binding. Details of the assay procedure are described
in Additional file 1 and have also been described else-
where [10].
Chemicals
All chemicals and buffers were sourced from VWR Life
Sciences, Sweden, unless otherwise noted. Peptides for
blocking (glucagon, GLP-1, etc.) were synthesized
in-house (Sanofi-Aventis, Frankfurt, Germany).
Radiochemistry
The 68Ge/68Ga generator was eluted with 0.1M HCl (3.5
mL). The pH of the eluate was adjusted to 4.6–5.0 by so-
dium acetate buffer (1M, 300 μL) containing sodium hy-
droxide (30 μL, 10M). To suppress the radiolysis and
formation of radioactive by-products, ethanol (200 μL) as a
radical scavenger was added to the reaction mixture. Then,
10 nmol of the precursor (DO3A-S01-GCG and
DO3A-S02-GCG) was added. The reaction mixture was
heated at 75 °C for 10–15min. The crude product was puri-
fied using a solid phase extraction cartridge (HLB, Oasis) to
assure elimination of possible hydrophilic radioactive im-
purities and germanium-68 and colloids. The product was
eluted with 1mL of 50% ethanol solution. The final product
was formulated dependent on the biological assay.
A sample was taken for determination of radiochemical
purity, peptide concentration, and pH. The total radio-
activity of the product was then measured in an ionization
chamber. Radiochemical purity and determination of the
concentration of the peptide were determined by
high-pressure liquid chromatography (HPLC). The HPLC
system (LaChrom, Hitachi, VWR) consisted of an L-2130
pump, a UV detector (L-2400), and a radiation flow de-
tector (Bioscan) coupled in series was used for product
quality control. Separation of the analytes was accom-
plished using an endcapped analytical column with sta-
tionary reversed phase (C-4; Vaydac-C4; 50 × 4.6mm;
particle size 3 μm). The following system was used: A =
10mM TFA; B = acetonitrile/10mM TFA with UV detec-
tion at 220 nm; linear gradient elution 0–8min from 24 to
44% B, 8–10min 44% B followed by re-equilibration 10–
10.5min from 44 to 24% B and 10.5–13min 24% B; flow
rate was 1.0 mL/min. Data acquisition and handling were
performed using the EZChrom Elite Software Package.
The stability of the product at room temperature in 50%
EtOH was monitored for 1–3 h and assessed by
UV-radio-HPLC.
Cellular internalization assay
HEK293 cells transfected with human GCGR (0.5 million
cells per dish) were incubated with 3–7 nM [68Ga]Ga-
DO3A-S01-GCG or [68Ga]Ga-DO3A-S02-GCG in 1mL
complete media at room temperature (RT) (5% CO2) for 0,
30, 60, 90, or 120min. The assay was also performed at 4 °C
(5% CO2) for 60 and 120min to suppress internalization.
The exact number of cells in each well was assessed by cell
counter. After incubation, the hot media containing the radi-
oligand was removed and the cells washed with serum-free
media two to three times while cells were put on ice.
To measure membrane bound and internalized radioli-
gand, cells were treated first with 0.2M glycine buffer
containing 4M urea (pH 2.5) (acid wash buffer) and sec-
ondly 1M NaOH (basic wash buffer).
Briefly, first 0.5 mL of acid wash buffer was added to the
cells and allowed to incubate for 5min on ice. The super-
natant was then removed and measured in a well counter
(membrane bound fraction) (Uppsala Imanet AB, Uppsala,
Sweden). The cells were washed one time, before 0.5 mL
of basic wash buffer was added and allowed to incubate
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for 30min at 37 °C. Then, the detached cells were col-
lected and measured by well counter (internalized frac-
tion). All samples were repeated in triplicates.
The well counter data for each dish and condition was
decay corrected to the time at the start of each experi-
ment and expressed as Bq. The internalized and the total
cell-associated (internalized + cell membrane bound)
fractions were expressed as percentage of the total added
radioligand per million of cells (%ID/M cells). The assay
was repeated three times using three different batches of
each radioligand.
Cell affinity assay
GCGR-transfected cells (approximately 0.5 million cells
per dish) were incubated at seven different concentrations
of [68Ga]Ga-DO3A-S01-GCG (0.3–300 nM) or [68Ga]Ga-
DO3A-S02-GCG (0.1–150 nM) around the expected Kd in
1mL complete media for 60min to reach steady state.
The cells were incubated with radiotracer alone or in the
presence of 10 μM endogenous glucagon peptide (to block
GCGR and assess non-specific binding). The assay was
performed at 4 °C to suppress internalization. After incu-
bation, the cells were washed two times with complete
media. For each dish, the cells were then trypsinized and
re-suspended, and the supernatant was measured for cell
density and radioactivity by the well counter (Uppsala
Imanet AB, Uppsala, Sweden). The well counter data was
decay corrected to the start of each experiment and con-
verted to pmol bound tracer per million cells (pmol/M
cells). Specific binding was determined by subtracting
non-specific binding from total binding.
All samples in each assay were repeated in triplicates,
and each experiment was repeated at least three times
with different batches of radioligand. Kd and Bmax for
the specific binding was calculated using non-linear
curve fitting in GraphPad Prism 6.05 (GraphPad, La
Jolla, CA, USA).
In vitro autoradiography assays
Liver and pancreas tissues were collected post-mortem
from cynomolgus monkeys (NHP) and Sprague Dawley
rats. The use of animal tissues collected post-mortem
was approved by the Animal Research Ethical Commit-
tee of the Uppsala Region and was performed according
to the Uppsala university guidelines on animal experi-
mentation (UFV 2007/724).
Biopsies from donor human liver and pancreas were
obtained from Uppsala Biobank (sample collection 827),
and their use was approved by local ethical review board
(EPN 2015/401).
Liver and pancreas frozen tissue sections (10 μm) from
healthy human, NHP, and rat, as well as sectioned frozen pel-
lets of HEK293 cells transfected with human GCGR (10 μm),
were incubated with 5–10 nM [68Ga]Ga-DO3A-S01-GCG or
[68Ga]Ga-DO3A-S02-GCG in 150mL phosphate-buffered sa-
line (PBS) (pH 7.4, 1% BSA) for 60min at RT. The sections
were incubated with radiotracer alone or together with
10 μM unlabelled precursor (S01-GCG or S02-GCG, respect-
ively, to assess non-specific binding), 10 μM glucagon (to as-
sess GCGR specific binding of each radiotracer), or 1 μM
GLP-1 (to assess cross-binding of the radiotracers to the
GLP-1R). Sections were added in duplicates in each individ-
ual assay, and each experiment was repeated at least three
times with different batches of radioligand, except for rat sec-
tions that were only performed in one assay.
After incubation, the sections were washed three times
in 150mL PBS. Sections were carefully dried at 37 °C and
then exposed against a digital phosphorimager plate over-
night together with a 10-μl droplet of radioactive reference
(cross-calibrated against a gamma counter) on an absorb-
ent paper attached to an object glass. The phosphor
imager plates were scanned using a Cyclone Plus Phos-
phor imager (Perkin Elmer) at 600 dpi, and the resulting
autoradiograms analyzed by ImageJ software (NIH, Be-
thesda). Pixel values in counts/mm2 were converted to
Bq/mm2 by the included reference. Bq/mm2 was further
converted to fmol/mm2 by the known specific radioactiv-
ity (fmol/Bq) of each batch of radiopharmaceutical.
Additionally, affinity of [68Ga]Ga-DO3A-S01-GCG was
assessed by in vitro autoradiography of sectioned frozen pel-
lets of GCGR-transfected cells. The same assay conditions
as above were used, unless otherwise stated. Cell pellet sec-
tions were incubated with eight different concentrations of
[68Ga]Ga-DO3A-S01-GCG (2–150 nM). Each concentra-
tion was measured as stand-alone samples, but the entire
experiment was performed twice. Non-specific binding was
assessed by co-incubation with 10 μM glucagon peptide
(GCG). Kd and Bmax for the specific binding was calculated
using non-linear curve fitting in GraphPad Prism 6.05.
Rat in vivo distribution
The in vivo distribution over time was performed to iden-
tify the optimal time point for an in vivo blocking study
and to calculate the residence time for dosimetry (see de-
tail below). Thus, measurement at more time points was
prioritized over repetitions at individual time points.
National and institutional guidelines for the care and
use of animals were followed. All procedures performed
in studies involving animals were in accordance with the
ethical standards of the institution or practice at which
the studies were conducted.
The in vivo organ distribution dynamics of [68Ga]Ga-
DO3A-S01-GCG and [68Ga]Ga-DO3A-S02-GCG were
assessed in Sprague Dawley rats (Taconic, Denmark) (327
± 18 g, male, n = 16 per radioligand). The animals were
kept at a constant temperature (25 °C) and humidity (50%)
in a 12-h light-dark cycle. Food and water were provided
ad libitum.
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Each radiotracer was administered into the tail vein of
conscious animals as a bolus in 0.5–0.6 mL of PBS (pH
7.4) as vehicle. Each animal received 3.9 ± 1.3 MBq/kg
(3.6 ± 1.3 μg/kg) [68Ga]Ga-DO3A-S01-GCG or 1.7 ± 0.5
MBq/kg (1.3 ± 0.4 μg/kg) [68Ga]Ga-DO3A-S02-GCG
radioactivity corresponding to 2–3 μg/kg peptide mass.
Given the constraints of the specific radioactivity for
each radioligand, the dosing was designed to minimize
the given peptide mass (in order to stay below mass ef-
fect levels) while still yielding enough radioactive signal
for well counter measurements.
At pre-determined post injection time points (5, 10,
20, 40, 60, 90, 120, and 180 min), two animals per each
point were euthanized by CO2. Tissues were immedi-
ately extracted and weighed, and the radioactive content
was measured in the well counter. The harvested organs
were the blood, heart, lung, liver, pancreas, spleen, ad-
renal, kidney, small intestine (without/with its content),
large intestine (without its content), feces, urinary blad-
der (rinsed), testis/ovary, muscle, bone, bone marrow,
thyroid, and brain. The well counter readings were decay
corrected to the time of injection and the mass of the
extracted tissues and expressed as Bq/cc. The measure-
ments were normalized to unitless standardized uptake
values (SUV) according to Eq. 1, to allow for direct com-
parison between the two radiotracers.
SUV
1
1
 
¼
Radioactivitytissue Bq
 
Weighttissue gð Þ
Radioactivityinjected Bq
 
Weightbody gð Þ
ð1Þ
Rat in vivo competition
A competition study with each respective radiotracer pre-
cursor peptide was performed to investigate in vivo selectiv-
ity in selected tissues (the blood, heart, lung, liver, pancreas,
spleen, kidney, muscle, and bone marrow). [68Ga]Ga-
DO3A-S01-GCG or [68Ga]Ga-DO3A-S02-GCG were ad-
ministered to conscious Sprague Dawley rats (Taconic,
Denmark) (283 ± 7 g, male, n = 8 per radioligand).
[68Ga]Ga-DO3A-S02-GCG (8.6 ± 1.7MBq/kg correspond-
ing to 6.4 ± 1.3 μg/kg) was administered in a higher radio-
active and mass dose than [68Ga]Ga-DO3A-S01-GCG (1.9
± 0.7MBq/kg corresponding to 1.4 ± 0.5 μg/kg), in order to
increase the relatively low detectable radioactive signal ob-
served in the liver in the biodistribution study.
Animals in each group (n= 4 for each radioligand) were
co-injected with 1mg/kg of either unlabelled
DO3A-S01-GCG or -DO3A-S02-GCG peptide to determine
the fraction of binding in each tissue which was receptor
mediated.
The animals were euthanized 40 or 60min after ad-
ministration of [68Ga]Ga-DO3A-S01-GCG or [68Ga]Ga--
DO3A-S02-GCG, respectively. The time point of
euthanasia for each radiotracer was determined based
on liver-to-blood ratio obtained from the biodistribution
study above, as well as the radionuclide half-life and
known radiotracer precursor half-life in blood plasma.
Tissue resection and analysis of radioactive uptake in
each tissue (expressed as SUV) were performed and ana-
lyzed as described above.
Human predicted dosimetry
The predicted dosimetry of [68Ga]Ga-DO3A-S01-GCG
or [68Ga]Ga-DO3A-S02-GCG in human males was esti-
mated based on the results from the rat in vivo biodistri-
bution described above. The dosimetry calculations were
performed as described previously for [68Ga]Ga--
DO3A-VS-Cys40-Exendin4 [11].
Briefly, animal-derived tissue uptake was normalized
to that of human tissues (using tissue weights of whole
body adult reference male and female phantoms). The
normalized SUVs were then un-decay corrected to their
respective time point to reflect the actual radiation bur-
den in each tissue. The tissue residence times (MBq-h/
MBq) were assessed by trapezoidal approximation of the
un-decay-corrected human SUV biodistribution data.
The tissue washout from the last time point (180 min) to
infinity was estimated by a single mono-exponential fit.
The estimation of the absorbed dose was performed
by the OLINDA/EXM 1.1 software (Vanderbilt Univer-
sity, USA) where the calculations were based on the
adult reference male or female phantoms to obtain the
intended absorbed dose estimate in humans (ICRP60).
The organ-specific doses are reported as mGy/MBq (ef-
fective dose as mSv/MBq). The amount of MBq that can
be safely administered annually (MBq/year) was calcu-
lated for each organ as well as the effective dose, by div-
iding the limiting dose (10 mSv/year for the effective
dose, 150 mGy/year for all tissues except for the red
marrow and uterus with 50 mGy/year) by the dose
(mGy/MBq or mSv/MBq).
Statistics
Data on group level are reported as mean ± SEM. Statis-
tical analysis was performed in GraphPad Prism 6.05
(GraphPad, La Jolla, CA, USA), and differences were
assessed by Student’s t test using a significance level of
P < 0.05.
Results
Potencies for the GCGR and GLP-1R
DO3A-S01-GCG and DO3A-S02-GCG activated the hu-
man, NHP, and rat GCGR with potencies in the picomo-
lar range (Table 1). The potency at the human GCGR
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was comparable to that of the native glucagon. Both
DO3A-S01-GCG and DO3A-S02-GCG exhibited >
50-fold selectivity than glucagon for activating GLP-1R.
Radiochemistry
Reliable and highly reproducible labelling synthesis with
control over the product peptide concentration and radio-
activity was developed and could be accomplished within
1 h. The eluate fractionation method was modified and
used for the production [12]. The parameters, time,
temperature, radical scavenger, buffer concentration, pH,
and product purification step, were investigated and opti-
mized using DO3A-S02-GCG and then applied to
DO3A-S01-GCG. The highest radiochemical yield was ob-
tained at 75 °C within 10–15min. The concentration of
acetate buffer was investigated in the range of 0.01–1M
with the highest radiochemical yield and robust produc-
tion obtained at 0.04M. The optimal pH value was found
to be 4.2–4.6. A number of solid phase extraction car-
tridges with reversed phase were tested for the purification
of the crude product. The highest peptide recovery of >
96% was found for hydrophilic-lipophilic-balanced car-
tridges. The pure product (Fig. 1) was eluted with 1ml of
50% EtOH and formulated in either isotonic sodium
chloride or phosphate-buffered saline. If required by the
biological assay, the formulated product was also sterile
filtered into a sterile 10-ml capped glass bottle. Quality
control was conducted using UV-radio-HPLC. Final prod-
uct purification excluded contamination with 68Ge and
colloids and provided high radiochemical purity (Table 2).
The difference in radiochemical yield (RCY) and radio-
chemical purity (RCP) for the tracers was marginal
(Table 2). The success rate (defined as RCP purity> 90%
and sufficient specific radioactivity in MBq/nmol for the
intended use of the batch) of the production was 100% for
both imaging agents. The amount of the starting radio-
activity used for the tracer production decreased with the
time according to the age of the generator, however, spe-
cific radioactivity values could be kept at least around 50
MBq/nmol (Table 2) in all experiments. Addition of EtOH
as a radical scavenger improved radiochemical purity.
The accurate determination of the peptide amount was
accomplished by UV-HPLC (Additional file 2: Figure S1B)
and assured reliability/reproducibility of the biological as-
says. An example of a typical UV-radio-chromatogram and
UV calibration plot for [68Ga]Ga-DO3A-S01-GCG is given
in Additional file 2: Figure S1. The stability of the tracers
was investigated during 2 h with RCP of over 91% (Add-
itional file 2: Figure S1A). The UV calibration plot covered
the range of peptide concentration expected in the final im-
aging agent product (Additional file 2: Figure S1B).
Cellular internalization
[68Ga]Ga-DO3A-S01-GCG bound to GCGR-transfected
cells reaching a steady state of approximately 65% ID/
million cells after 60–120 min (Fig. 2a). The internalized
fraction was 30–40% of the total binding and could be
suppressed almost completely by cooling. Binding of
[68Ga]Ga-DO3A-S02-GCG tended to be lower than that
of [68Ga]Ga-DO3A-S01-GCG and reached a plateau of
approximately 40% ID/million cells after 60 min (Fig. 2b).
The internalized fraction of [68Ga]Ga-DO3A-S02-GCG
was 30% and again suppressed by cooling.
Affinity
[68Ga]Ga-DO3A-S01-GCG binding to GCGR-transfected
cells could be inhibited by 10 μM GCG. Saturation bind-
ing experiments in viable cells displayed a Kd of 18.8 ±
10.1 nM (n = 3) (Fig. 2c). For [68Ga]Ga-DO3A-S02-GCG,
it was not possible to obtain a clear saturation of binding
in the range of 0.1–150 nM and the affinity was estimated
to be > 100 nM (n = 4) (Fig. 2d). Further optimization of
this value was not performed as this affinity was deemed
too low to merit further exploration.
[68Ga]Ga-DO3A-S01-GCG saturation binding experi-
ments of section of frozen pellets of GCGR-transfected
cells yielded similar affinity as the live cell assay (Kd =
14.2 ± 1.0 nM (n = 2) (Fig. 2f ).
In vitro autoradiography
[68Ga]Ga-DO3A-S01-GCG binding to liver sections in ei-
ther NHP, human, or rat could be inhibited > 60% by
co-incubation with GCG (Fig. 3a, d) (NHP, n = 3, p = 0.11;
human, n = 3, p < 0.05; rat, n = 1, p =N/A). Co-incubation
with the DO3A-S01-GCG precursor peptide in excess did
not increase the degree of inhibition (NHP, n = 3, p = 0.18;
human, n = 3, p < 0.05; rat, n = 1, p =N/A). Addition of
GLP-1 in excess did not induce inhibition of [68Ga]Ga-
DO3A-S01-GCG binding (NHP, n = 3, p = 0.43; human, n
= 3, p = 0.35; rat, n = 1, p =N/A).
Table 1 Potencies of S01-GCG and S02-GCG at the GCGR and GLP-1R in transfected HEK293 cells
Peptide Human Cynomolgus monkey Rat
GCGR (pM) GLP1R (pM) GCGR (pM) GLP1R (pM) GCGR (pM) GLP1R (pM)
DO3A-S01-GCG 0.4 19,734 1.2 4812 11.2 16,884
DO3A-S02-GCG 0.8 4611 7.9 1980 47.6 3960
Native GCG 0.5 28 1.2 31 7.5 39
All values are EC50 given as pM
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Only background binding was observed in the pancreas
section regardless of species and was unaffected by the
addition of either the GCG, GLP-1, or DO3A-S01-GCG
precursor peptide (Fig. 3b) (NHP, n = 3; human, n = 3; rat,
n = 1). Binding of [68Ga]Ga-DO3A-S01-GCG to sections of
frozen pellet of GCGR-transfected cells (n = 3) was very
strong and could be completely abolished by co-incubation
with the GCG (p < 0.05) or DO3A-S01-GCG precursor
peptide (p < 0.05), but not GLP-1 (Fig. 3c).
[68Ga]Ga-DO3A-S02-GCG binding to liver sections was
lower in magnitude than [68Ga]Ga-DO3A-S01-GCG, but
similarly inhibited by > 50% by co-incubation with the
GCG (NHP, n = 4, p < 0.05; human, n = 3, p < 0.05; rat, n =
1, p =N/A) and DO3A-S02-GCG precursor peptide
(NHP, n = 4, p = .012; human, n = 3, p = 0.19; rat, n = 1, p
=N/A) (Fig. 3e, h). Addition of GLP-1 had no inhibitory
effect on [68Ga]Ga-DO3A-S02-GCG binding (NHP, n = 4,
0.95; human, n = 3, p = 76; rat, n = 1, p =N/A). Pancreas
binding was low and non-specific (Fig. 3f) (NHP, n = 4;
human, n = 3; rat, n = 1).
Binding to GCGR-transfected cells (n = 3) was again
lower in magnitude than for [68Ga]Ga-DO3A-S01-GCG
and inhibited by GCG (p = 0.07) and DO3A-S02-GCG
precursor peptide (p = 0.16), but not GLP-1 (Fig. 3g).
Rat in vivo biodistribution
Rapid biodistribution and subsequent washout in all tis-
sues except the liver, spleen, kidney, and bone marrow
was seen following administration of [68Ga]Ga-
DO3A-S01-GCG (Fig. 4a and Additional file 3: Table
S1). Uptake in the liver reached a plateau of approxi-
mately SUV 3 after 20 min. The liver-to-blood ratio in-
creased continuously and was > 30 after 90 min (Fig. 4b).
Similar biodistribution observations were made for
[68Ga]Ga-DO3A-S02-GCG, but the retention in the liver
(SUV < 1), spleen, and bone marrow was lower compared
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Table 2 Results of 68Ga-labelling of DO3A-S01-GCG and DO3A-S02-GCG
Radiotracer NDC RCY [%] SRA @ EOS [MBq/nmol] RA @ EOS [MBq] RCP [%] Amount [nmol] Number Success rate [%]
[68Ga]Ga-DO3A-S01-GCG 61.0 ± 2.0 50.2 ± 5.4 348 ± 30 98.8 ± 0.4 7.2 ± 0.5 9 100
[68Ga]Ga-DO3A-S02-GCG 56.9 ± 1.3 64.9 ± 2.1 471 ± 31 95.4 ± 1.4 6.96 ± 0.14 10 100
NDC RCY non-decay-corrected radiochemical yield, SRA specific radioactivity, EOS end of the synthesis, RA radioactivity, RCP radiochemical purity
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to that for [68Ga]Ga-DO3A-S01-GCG (Fig. 4c and Add-
itional file 4: Table S2). Accordingly, [68Ga]Ga--
DO3A-S02-GCG liver-to-blood ratio was a modest 3 after
90min (Fig. 4d).
Rat in vivo competition
[68Ga]Ga-DO3A-S01-GCG binding in the liver, spleen,
and bone marrow was decreased by > 80% by
co-injection of 1 mg/kg of the DO3A-S01-GCG precur-
sor peptide (Fig. 5a). The high kidney uptake was not af-
fected, nor uptake in all other examined tissues.
For [68Ga]Ga-DO3A-S02-GCG, binding in the liver and
spleen was reduced by 56 and 60% respectively, but from
a lower baseline of approximately SUV 0.5 (Fig. 5b).
Direct comparison in the liver shows that [68Ga]Ga-
DO3A-S01-GCG has higher receptor specificity (de-
creased 84% by precursor peptide inhibition) as well as
higher baseline binding (SUV > 2) than [68Ga]Ga-
DO3A-S02-GCG (Fig. 5c).
Human predicted dosimetry
The absorbed dose is predicted to be highest in the kidneys
(0.53 and 0.48mGy/MBq) for [68Ga]Ga-DO3A-S01-GCG
and [68Ga]Ga-DO3A-S02-GCG, respectively (Fig. 6a). The
kidneys were followed by the myocardium (heart wall)
which also receives most of its radiation dose from the
passing blood. The absorbed dose in the liver, spleen, and
red marrow were somewhat higher for [68Ga]Ga-
DO3A-S01-GCG as expected from the pronounced reten-
tion seen in the biodistribution. The whole body effective
dose was also higher for [68Ga]Ga-DO3A-S01-GCG
(20.2 μSv/MBq) compared to [68Ga]Ga-DO3A-S02-GCG
(16.6 μSv/MBq), reflecting the generally higher binding and
tissue retention.
Regarding the calculated maximal annual dosing (in
MBq), the kidney dose is limiting with 278 and 312MBq
for both [68Ga]Ga-DO3A-S01-GCG and [68Ga]Ga-
DO3A-S02-GCG, respectively (Fig. 6b). The whole body
effective dose limits the annual exposure to 495 and 602
MBq, respectively. The bone marrow absorbed dose for
[68Ga]Ga-DO3A-S01-GCG is predicted to allow for an
excess of 2000MBq administered annually.
Discussion
The development of novel anti-diabetic therapies targeting
glucagon receptors (GCGR) either by itself or as part of
dual GLP-1/GCG agonists will profit substantially from
employment of imaging techniques that enable in vivo in-
vestigation of GCGR engagement by the therapeutic agent
to facilitate stratification of candidate drugs. Herein, we
present radiochemistry and preclinical evaluation of two
novel peptide-based analogues targeting GCGR for PET
0 20 40 60 80 100 120
0
20
40
60
80
100
Time (min)
%
ID
/ m
ill
io
n 
ce
lls
[68Ga]Ga-DO3A-S01-GCG
0 20 40 60 80 100 120
0
20
40
60
80
100
Time (min)
%
ID
/ m
ill
io
n 
ce
lls
[68Ga]Ga-DO3A-S02-GCG
0 100 200 300
0
5
10
15
20
25
30
35
40
45
Added [68Ga]DO3A-S01-GCG (nM)
B
ou
nd
 (p
m
ol
/m
ill
io
n 
ce
lls
)
[68Ga]Ga-DO3A-S01-GCG
0 25 50 75 100 125 150
0
1
2
3
4
5
6
Added [68Ga]DO3A-S02-GCG (nM)
B
ou
nd
 (p
m
ol
/m
ill
io
n 
ce
lls
)
[68Ga]Ga-DO3A-S02-GCG
0 50 100 150
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Added [68Ga]DO3A-S01-GCG (nM)
B
ou
nd
 (p
m
ol
/m
ill
io
n 
ce
lls
)
[68Ga]Ga-DO3A-S01-GCG (ARG)
Internalized
Total cell associated
Internalized, 4 C
Total cell associated, 4 C
Total bound Non-specific bound Specific bound
A B
C D E
Fig. 2 Cellular internalization and GCGR affinity of [68Ga]Ga-DO3A-S01-GCG and [68Ga]Ga-DO3A-S02-GCG. Binding and internalization in HEK293
cells overexpressing human GCGR of [68Ga]Ga-DO3A-S01-GCG (a) and [68Ga]Ga-DO3A-S02-GCG (b). Internalization was suppressed by cooling cells
to 4 °C. Affinity was measured in HEK293 cells overexpressing human GCGR by saturation binding studies on viable cells (c, d) or by in vitro
autoradiography (ARG) on sections of cell pellet (e)
Velikyan et al. EJNMMI Research            (2019) 9:17 Page 7 of 13
imaging that enables accurate quantification and evalu-
ation of the target receptor occupancy.
In vitro evaluation indicated high potency of both pep-
tide precursors for the GCGR in transfected cells, in the
same range as native glucagon, but with negligible acti-
vation of the GLP-1R. The gallium-68-radiolabeled
peptides exhibited strong binding to GCGR-transfected
cells as well as GCGR-rich liver tissue from rat, NHP,
and human. Internalization occurred as expected from
an agonist, indicated to be an active process as it was
suppressed at low temperatures. The binding in trans-
fected cells as well as liver tissue was GCGR mediated,
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Fig. 3 In vitro autoradiography of [68Ga]Ga-DO3A-S01-GCG or [68Ga]Ga-DO3A-S02-GCG. Binding of [68Ga]Ga-DO3A-S01-GCG to sections of the
liver (a) and pancreas (b) from NHP (n = 3), human (n = 3), or rat (n = 1), or HEK293 cells overexpressing GCGR (n = 3) (c). Representative
autoradiograms of [68Ga]Ga-DO3A-S01-GCG binding in the human liver (d). Binding of [68Ga]Ga-DO3A-S02-GCG to sections of the liver (e) and
pancreas (f) from NHP (n = 3), human (n = 3), or rat (n = 1), or HEK293 cells overexpressing GCGR (n = 3) (g). Representative autoradiograms of
[68Ga]Ga-DO3A-S02-GCG binding in the human liver (h). The sections were incubated either with radiotracer alone (Total) or together with 10 μM
GCG, 1 μM GLP-1, or 10 μM of respective tracer precursor peptide S01-GCG or S02-GCG. Stars or p values above bars indicate difference compared
to the total binding
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as it could be inhibited by native glucagon. Co-incubation
with the precursor peptide itself did not yield any additional
inhibition effect on [68Ga]Ga-DO3A-S01-GCG or [68Ga]Ga-
DO3A-S02-GCG binding compared to native glucagon, indi-
cating that both radiotracers are specific for GCGR.
Due to the structural similarity and shared transcrip-
tional origin of the native peptides GCG and GLP-1,
cross-binding to GLP-1R is a distinct possibility for any
GCGR targeting agent [13]. Native glucagon for example,
which was previously radiolabeled with long-lived SPECT
nuclides, could potentially interact with both GCGR as
well as GLP-1R, depending on exposure [14, 15]. How-
ever, careful design of the tracer compounds based on
structural insights into both the GCG and GLP-1 receptor
[10] led to negligible cross-binding of either radiotracer in
this study as indicated by both the lack of inhibitory effect
of GLP-1 on [68Ga]Ga-DO3A-S01-GCG or [68Ga]Ga-
DO3A-S02-GCG binding, as well as the low baseline
binding in the GLP-1R-rich pancreas.
The higher binding of [68Ga]Ga-DO3A-S01-GCG in cells
and tissues, as compared to [68Ga]Ga-DO3A-S02-GCG, is
likely explained by the improved affinity which was in the
range of 10–20 nM regardless of the assay as well as im-
proved pharmacokinetics (plasma t½ increased from 0.12 to
0.25 h and exposure increased from 325 to 1570 h ng/mL,
data not shown). As a comparison, the affinity of [68Ga]Ga-
DO3A-VS-Cys40-Exendin-4, already an established PET
marker for GLP-1R receptor occupancy, has an affinity of
Kd = 10.7 ± 3.5 nM when measured by in vitro autoradiog-
raphy on human insulinoma section [16]. [68Ga]Ga-
DO3A-S01-GCG thus has an affinity in the range suitable
for quantitative in vivo PET sensing of receptor interactions.
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Based on the in vitro results, strong binding and sub-
sequent internalization of the radiotracers is expected
also in vivo. After peptide digestion in the cytosol,
68Ga(III) remains normally in a charged state unable to
passively cross the cell membrane. Thus, strong reten-
tion of 68Ga(III) radioactive signal is expected in tissues
with GCGR expression.
Accordingly, [68Ga]Ga-DO3A-S01-GCG displayed an
improvement compared to [68Ga]Ga-DO3A-S02-GCG in
vivo in rat. The retention in target tissue liver was sub-
stantially higher, and the fraction that could be com-
peted away was higher. The liver-to-blood ratio (or
image contrast) was more than 30 after 90 min, indicat-
ing that the interference from the blood was minimal.
Again, [68Ga]Ga-DO3A-S01-GCG displays similar mag-
nitude of binding in the GCGR-rich liver as well as simi-
lar degree of receptor specificity as the established
receptor occupancy PET agent [68Ga]Ga-DO3A-VS-Cy-
s40-Exendin-4 does in the GLP1R-rich pancreas [5, 7]. In
summary, the strong signal seen for [68Ga]Ga-
DO3A-S01-GCG in the liver represents GCGR-mediated
binding. This represents a large dynamic range where
changes in GCGR availability—such as receptor occu-
pancy by a candidate drug—can be quantified.
Antagonists are often preferred to agonists when de-
veloping radioligands intended for target engagement or
occupancy measurement. Here, it was deemed more
straightforward to develop a highly specific GCGR bind-
ing peptide agonist, due to the accumulated knowledge
on the interactions of several endogenous and synthetic
agonistic peptides (including native GCG, GLP-1, and
Exendin4) to GCGR. In addition, the availability of an
established high-throughput cell assay for potency
assisted in the development of a library of agonists to-
wards GCGR. For internalizing agonists in combination
with residualizing radionuclides, as is the case here, it is
suitable to consider the net rate uptake or volume of
distribution as a snapshot of the receptor availability at
the time of the PET examination.
The increased retention in the liver, spleen, and bone
marrow for both radiotracers was receptor mediated
based on the competition study. The kidney signal likely
represents excretion of either radiotracer. Peptides with
a mass < 60 kDa enter glomerular filtration in the kidney
and may then be reabsorbed by the renal tubules and
68Ga(III) retained by the mechanism described above.
GCGR expression has been described in the kidneys
[17], but the strong excretion-mediated signal most
likely masks any signal from receptor binding which ex-
plains the absence of measurable inhibition in competi-
tion studies. The binding in the spleen to a considerable
extent represents receptor-mediated binding as indicated
by the competition study, which is verified by previous
expression studies in rat [18]. This is possibly a
species-specific observation as GCGR expression has
not been confirmed in the human spleen [17]. The bind-
ing to the bone marrow of [68Ga]Ga-DO3A-S01-GCG
(Figs. 4a and 5a) and to a lesser extent [68Ga]Ga-
DO3A-S02-GCG (Fig. 4c) is similarly likely species
dependent since GCGR has not previously been re-
ported in human. It can be speculated to be related to
immune cells in rat, given the binding to both the spleen
and bone marrow. The binding to the bone again repre-
sents the bone marrow, since the “bone” measurement
in the assay contains the whole femur (both the cortical
bone and the bone marrow).
In order to allow for measurement of GCGR occu-
pancy of a dual GLP-1/GCG receptor agonist, the dos-
imetry must allow for at least two repeated PET
examinations in an individual (i.e., scanning at baseline
and again following drug treatment).
The predicted human dosimetry extrapolated from rat
biodistribution shows that the renal dose is the limiting
one for both tracers evaluated here. This is common for
small peptides labeled with residualizing radionuclides
such as gallium-68. When considering the possibility of
repeated PET scanning, the maximal possible annual
dosing (MBq) to a human individual is inversely corre-
lated on the absorbed dose. Additionally, it depends on
the regulatory safety limit set for each tissues (as de-
scribed in the “Materials and methods” section above).
The limiting injection dose was estimated to 278MBq
for the kidney in the case of [68Ga]Ga-DO3A-S01-GCG.
Assuming an administered radioactivity dose of 75
MBq per human examination, three annual PET exami-
nations of GCGR occupancy in healthy individuals or in-
dividuals with T2D would be possible. Given that
modern PET/CT scanners have improved sensitivity,
combined with minimizing potential peptide mass ef-
fects on occupancy, it is likely that a radioactive dose of
50MBq is more reasonable. This scenario would allow
for up to five annual examinations of GCGR occupancy,
without exceeding the radiation safety limits for the pre-
dicted kidney absorbed dose.
A similar calculation on the whole body effective dose
(assuming 75MBq [68Ga]Ga-DO3A-S01-GCG and an
associated low-dose anatomical CT scan of 0.4 mSv)
would allow for up to five PET/CT examinations. The
annual scanning possible for [68Ga]Ga-DO3A-S02-GCG
is similar as calculated for [68Ga]Ga-DO3A-S01-GCG.
Regardless of the assumptions, the dosimetry of either
radiotracer would allow for both measurement of hep-
atic liver occupancy during basal physiology and follow-
ing drug intervention with for example a dual GLP-1/
GCG receptor agonist.
In summary, [68Ga]Ga-DO3A-S01-GCG demonstrated
favorable characteristics as a promising candidate pep-
tide for in vivo monitoring of GCGR occupancy in
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humans. The possibility of quantitative GCGR PET im-
aging will potentially assist in pharmaceutical develop-
ment as well as improved understanding of the human
GCGR signaling in healthy and metabolic disease.
Conclusion
We present evidence of first-in-class PET tracers target-
ing the GCG receptor. [68Ga]Ga-DO3A-S01-GCG has
suitable properties for development as clinical PET ra-
diotracer. This tool has potential to provide direct quan-
titative evidence of GCG receptor occupancy in humans.
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